The following represents disclosure information provided by authors of this abstract. ASCO's Quality Care Symposium Planning Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Community oncology treatment patterns and clinical effectiveness in metastatic castration-resistant prostate cancer (mCRPC) patients who progressed after docetaxel.
Arthur C. Houts
Research Funding - Sanofi
Daniel Hennessy
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Mark S. Walker
Research Funding - Sanofi
Leonardo Nicacio
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Honoraria - Sanofi
Stephen F. Thompson
Employment or Leadership Position - Sanofi
Paul J. E. Miller
No relevant relationships to disclose
Bradley G. Somer
No relevant relationships to disclose